Claritas Pharmaceuticals, Inc.

CLAZFOTCHealthcare● Active

$0.00

+$0.00(+0.00%)

Market Cap$3659

P/E Ratio—

52W High$0.0001

52W Low$0.0001

Avg Volume237.712

Open$0.00

Beta1.64

Earnings Financials Revenue

Claritas Pharmaceuticals, Inc. (CLAZF) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

CLAZF · earnings · updated Jun 8, 2026

Latest Earnings

Q3 FY2021Report Date: Sep 30, 2021

EPS Actual

$0.01

Revenue

—

Fiscal Period

Q3 FY2021

FY ends December

Report Date

Sep 30, 2021

After Market Close

CLAZF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

$0.21

Rev. $0.66B

Days Away85

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.$0.21

Rev. Est.$0.66B

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
◌ Q3 FY2026	Aug 31, 2026	—	—	—	—	—	—
◌ Q2 FY2026	May 29, 2026	—	—	—	—	—	—
◌ Q2 FY2026	May 29, 2026	—	—	—	—	—	—
◌ Q1 FY2026	Feb 25, 2026	—	—	—	—	—	—
— Q3 FY2021	Sep 30, 2021	—	$0.01	—	—	—	—
— Q2 FY2021	Jun 30, 2021	—	-$0.06	—	—	—	—
— Q1 FY2021	Mar 31, 2021	—	-$0.08	—	—	—	—
— Q4 FY2020	Dec 31, 2020	—	$0.04	—	—	—	—

Q3 FY2026

Aug 31, 2026

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2026

May 29, 2026

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2026

May 29, 2026

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q1 FY2026

Feb 25, 2026

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q3 FY2021

Sep 30, 2021

EPS Actual

$0.01

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2021

Jun 30, 2021

EPS Actual

-$0.06

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q1 FY2021

Mar 31, 2021

EPS Actual

-$0.08

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q4 FY2020

Dec 31, 2020

EPS Actual

$0.04

EPS Est.

—

EPS Surpr.

—

Revenue

—

Analyst Estimates

EPS Estimates

Period	Low	Consensus	High	# Analysts

Revenue Estimates

Period	Low	Consensus	High	# Analysts

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
— Q3 FY2021	Sep 30, 2021	—	$0.01	$0.01	-12.24%
— Q2 FY2021	Jun 30, 2021	—	$0.01	$0.01	+5.77%
— Q1 FY2021	Mar 31, 2021	—	$0.02	$0.02	+0.00%
— Q4 FY2020	Dec 31, 2020	—	$0.00	$0.00	+900.00%
— Q4 FY2020	Oct 2, 2020	—	$0.00	$0.00	+0.00%
— Q2 FY2020	Jun 30, 2020	—	$0.01	$0.01	-49.83%
— Q1 FY2020	Mar 31, 2020	—	$0.00	$0.00	+1.12%
— Q4 FY2019	Dec 31, 2019	—	$0.02	$0.02	+6.29%

Q3 FY2021-12.24%

Report Date

Sep 30, 2021

EPS Beat/Miss

—

Price Before

$0.01

Price After

$0.01

Q2 FY2021+5.77%

Report Date

Jun 30, 2021

EPS Beat/Miss

—

Price Before

$0.01

Price After

$0.01

Q1 FY2021+0.00%

Report Date

Mar 31, 2021

EPS Beat/Miss

—

Price Before

$0.02

Price After

$0.02

Q4 FY2020+900.00%

Report Date

Dec 31, 2020

EPS Beat/Miss

—

Price Before

$0.00

Price After

$0.00

Q4 FY2020+0.00%

Report Date

Oct 2, 2020

EPS Beat/Miss

—

Price Before

$0.00

Price After

$0.00

Q2 FY2020-49.83%

Report Date

Jun 30, 2020

EPS Beat/Miss

—

Price Before

$0.01

Price After

$0.01

Q1 FY2020+1.12%

Report Date

Mar 31, 2020

EPS Beat/Miss

—

Price Before

$0.00

Price After

$0.00

Q4 FY2019+6.29%

Report Date

Dec 31, 2019

EPS Beat/Miss

—

Price Before

$0.02

Price After

$0.02

Beat Rate0 / 8 quarters

Largest Move+900.00% (Q4 FY2020)

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

Claritas Pharmaceuticals, Inc. (CLAZF) most recently reported earnings on September 30, 2021 for Q3 FY2021, posting EPS of $0.01 (in line with the analyst consensus of —). The next CLAZF earnings date is expected around September 1, 2026.

Each quarter, investors track CLAZF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CLAZF revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

CLAZF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

CLAZF earnings · 4 questions

Claritas Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. CLAZF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CLAZF historically reports after market close (AMC).

CLAZF earnings datewhen is CLAZF earningsCLAZF next earnings datewhen does CLAZF report earningsCLAZF earnings calendar

▸ Source: FMP · Claritas Pharmaceuticals, Inc. SEC filings · US GAAP · Claritas Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026